EU regulators back AstraZeneca thyroid cancer drug (Reuters, 18 November 2011)

18 Nov 2011


The European Medicines Agency has adopted a positive opinion of AstraZeneca's vandetanib (trade name Caprelsa) for the treatment of advanced and non-operable medullary thyroid cancer.

Full article


Share this story